Tag : NEUROMYELITIS OPTICA SPECTRUM DISORDER

Satralizumab is a monoclonal recycling antibody that targets the interleukin-6 receptor (IL-6R). Two randomized, placebo-controlled, phase 3 clinical trials, SakuraSky and SAkuraStar, had demonstrated the significant reductive effect and favorable safety and tolerability profile of 120mg satralizumab subcutaneous (SC) administration in the risk of relapse in patients with aquaporin-4 immunoglobulin G seropositive (AQP4-IgG+) neuromyelitis optica spectrum disorder (NMOSD).